Recent Finacing
Recent Raise
Tolera Therapeutics develops immunotherapeutics—primarily monoclonal antibody TOL101 for prevention of acute organ rejection—built on academic research and preparing Phase 3 clinical testing with an FDA SPA submission.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
